Levetiractam in the treatment of two children with myoclonic status epilepticus

被引：11

作者：

Haberlandt, E. ^{[1
]}

Sigl, S. Baumgartner ^{[1
]}

Scholl-Buergi, S. ^{[1
]}

Karall, D. ^{[1
]}

Rauchenzauner, M. ^{[1
]}

Rostasy, K. ^{[1
]}

机构：

[1] Med Univ Innsbruck, Dept Pediat, Div Neuropediat & Inherited Metab Disorders, A-6020 Innsbruck, Austria

来源：

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY | 2009年 / 13卷 / 06期

关键词：

Levetiracetam; Intravenous; Myoclonic status epilepticus; Children; NONCONVULSIVE STATUS EPILEPTICUS; EPILEPSY; PIRACETAM;

D O I：

10.1016/j.ejpn.2008.09.006

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Levetiracetam (LEV) is approved as second line treatment for partial onset seizures in adults and children older than four years of age. Recently, an intravenous formulation was developed as an alternative to standard oral medication. We report the successful treatment of two children suffering from myoclonic status epilepticus with intravenous LEV. Intravenous application of LEV was safe and not associated with significant side effects. In conclusion, intravenous application of LEV appears to be a further option in treatment of children with myoclonic status epilepticus. (C) 2008 Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.

引用

页码：546 / 549

页数：4

共 23 条

[1] Nonconvulsive status epilepticus on treatment with levetiracetam [J].